Indiana

Melanoma Clinical Trials- Recruiting

Phase
NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery		 Phase III
NCT01006980
A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)		 Phase III
NCT01227889
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma		 Phase III
NCT00940225
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies		 Phase II
NCT01120275
RO4929097 in Treating Patients With Stage IV Melanoma		 Phase II
NCT00049530
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma		 Phase II
NCT00976573
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma		 Phase II
NCT00976573
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma		 Phase II
NCT00815607
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma		 Phase I
NCT01397708
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma		 Phase I
NCT01397708
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma		 Phase I
NCT01264380
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma		 Phase I
Updated from clinicaltrials.gov on 8/24/2011

Comments are closed.